1.86
+6.90%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Black Diamond Therapeutics
From its filings with the US Securities and Exchange Commission
Black Diamond Therapeutics is based in Cambridge, Massachusetts. Its shares trade on Nasdaq under the ticker BDTX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $70.0m and net income of $22.4m. At that date it held total assets of $143.0m and shareholders' equity of $112.2m.
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat central nervous system (CNS) disease. Our compounds target families of oncogenic mutations in clinically validated pathways. Our lead clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). We plan to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed patients with EGFR altered glioblastoma (GBM) in the second quarter of 2026.
Our MasterKey therapies were discovered using our proprietary MAP drug discovery engine which was built on three central pillars: identification of oncogenic mutations, confirmation of oncogenicity of mutations based upon cell and tumor models, and pharmacologic inhibition of the relevant mutations while sparing wild-type.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jan 2020
- Employees
- 21
- Website
- blackdiamondtherapeutics.com ↗
- Head office
- 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Mark VellecaChairman of the Board, President, Chief Executive Officer, since 2021$2.9m
- Dr. Elizabeth BuckCo-Founder, Chief Scientific Officer
- Ms. Erika JonesSenior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
- Mr. Brent Hatzis-SchochChief Operating Officer, General Counsel$1.4m
- Ms. Melanie MorrisonChief Development Officer
- Dr. Sergey YurasovChief Medical Officer$1.5m
- Dr. Samarth KulkarniLead Independent Director$171,347
- Dr. Ali BehbahaniIndependent Director$159,847
- Ms. Shannon CampbellIndependent Director$352,200
- Dr. Kapil DhingraIndependent Director$186,747
- Dr. Garry MenzelIndependent Director$162,347
- Dr. Prakash RamanIndependent Director$356,896
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 55
- Environment
- 55
- Social
- 90
- Governance
- 21
- Women in the workforce
- 58%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Black Diamond Therapeutics Inc. utilizes advanced technologies in the field of precision oncology, allowing for the development of innovative therapies.
- The company has a robust and diversified pipeline of targeted therapeutics, which reduces dependency on a single product or approach.
Weaknesses
- As a relatively new entrant in the market, Black Diamond Therapeutics Inc. may face challenges in establishing its brand and gaining market share.
- The company's financial resources and operational capabilities might be limited, which could impact research and development activities.
Opportunities
- With growing awareness and understanding of precision medicine, the demand for targeted therapies is expected to rise, presenting an opportunity for Black Diamond Therapeutics Inc.
- Expanding into emerging markets provides the company with access to a larger patient population and potential for increased revenue.
Threats
- The presence of established pharmaceutical companies in the precision oncology field may pose a threat to Black Diamond Therapeutics Inc.'s market share and growth.
- Stringent regulatory requirements in the healthcare industry can create barriers to entry for new therapies, which could potentially hinder the company's progress.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.